GSK-3342830

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameGSK-3342830
Drug Alias NameGSK-830GSK-3342830RSC-435830
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCell wall inhibitors
TargetsNot applicable
Therapy Area/IndicationsBacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsBacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A